The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma

<div>Clinical course of the patient after front-line treatment showing (a) PET-interim partial remission after induction ABVD chemotherapy; (b) PET/CT after completion of 6 cycles reveals complete remission and clinical improvement.</div>

Case Reports in Hematology

fig1

Figure 1

Figure 1: The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma 

Figure 1 | The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma 